Government promoting acceptance of Indian drug norms in various markets
The government is in talks with various semi regulated markets like Myanmar and Kenya to accept its drug norms which will help many of the Indian drug makers to save on costs required to upgrade to international standards.
November 29, 2015: Pharmaceuticals Export Promotion Council of India (Pharmexcil) is in talks with various semi regulated markets in Africa, ASEAN, SAARC regions to accept the Indian Pharmacopoeia instead of British Pharmacopoeia (BP) or the United States Pharmacopoeia (USP). To build up support for the initiative, Pharmexcil has invited 10-15 drug regulatory heads from various countries to take part in the Indian Pharmaceutical Congress in Mysore in December, 2015.
Pharmacopoeia stands for a set of standards and quality specifications for ingredients, preparation and dosage forms of medicines that are manufactured, sold, consumed and exported in a country.The Indian Pharmacopoeia Commission (IPC) is an autonomous institution under the Ministry of Health and Family Welfare.
It is expected that the move would help Indian drug makers that only follow IPC to save costs and time for them to upgrade and adopt either BP or USP. However the task to convince these countries would not be easy as confidence has to be instilled in them regarding Indian manufacturing facilities and standards, according to Pharmexcil.